# Multicenter Trial to Treat Patients With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma

> **NCT00884286** · PHASE2 · COMPLETED · sponsor: **PharmaMar** · enrollment: 67 (actual)

## Conditions studied

- Leukemia
- Lymphoma

## Interventions

- **DRUG:** Aplidin®

## Key facts

- **NCT ID:** NCT00884286
- **Lead sponsor:** PharmaMar
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** 2010-06
- **Final completion:** 2010-06
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2018-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00884286

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00884286, "Multicenter Trial to Treat Patients With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00884286. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*